Navigation Links
Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV
Date:9/14/2009

PRINCETON, N.J. and SAN DIEGO, Sept. 14 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomized study of TBR-652 in sixty healthy volunteers. TBR-652, a CCR5 antagonist under investigation for the treatment of HIV, was evaluated at doses ranging from 25 mg once daily (QD) to 200 mg QD after a high fat meal. Pharmacokinetic parameters were measured on Days 1 and 10, while safety and tolerability were evaluated throughout the 10 day study. The results of the study demonstrate TBR-652 was well tolerated in all groups. TBR-652 reached maximum plasma exposure 3-6 hours post dose on Days 1 and 10. Mean plasma half-life ranged from 40 to 45 hours, supporting once daily dosing. Exposure pharmacokinetic measures were greater than the therapeutic level projected from in vitro studies of TBR-652.

"This Phase I study provides further clinical support for the continued development of TBR-652 in the treatment of HIV. We are very encouraged by the excellent exposure results from the study and look forward to results from ongoing trials," said James Sapirstein, CEO.

These data were presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 12-15, 2009 in San Francisco, California. The poster presentation can be viewed at www.tobiratherapeutics.com.

About Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disea
'/>"/>

SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
2. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
3. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics Board of Directors as Chair
6. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
7. PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
8. /C O R R E C T I O N -- Clinical Therapeutics/
9. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
11. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument (Liquid ... Valves, Guages, Seals), Accessories, Services, End User (Biotechnology, ... provides a detailed overview of the major drivers, ... impacting the preparative and process chromatography market along ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 On ... H.R. 83, the Omnibus and Continuing Resolution Appropriations Act ... a condition eligible to receive funding through the Congressionally ... of Defense (DoD). The Hydrocephalus Association (HA), working in ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... Board: SYMD), a biomaterials company engaged in the development,and ... Robert P. Hickey, President and CEO, will present at,the ... 2007 at,5:05 PM, EDT, at the New York Palace ... company overview. The presentation will be available via ...
... the Delft University of Technologys Kavli Institute of Nanoscience ... have succeeded in controlling the spin of a single ... way for a much simpler realization of the building ... will publish their work in Science Express on Thursday ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), a biopharmaceutical ... medicines in the areas of hepatitis C and,oncology, ... quarter ended,September 30, 2007 and operational highlights. ... transition for Anadys,",said Steve Worland, Ph.D., President and ...
Cached Biology Technology:Delft University of Technology rotates electron spin with electric field 2Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 8Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 9
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... May 30, 2011 Reportlinker.com announces that ... in its catalogue: Enzymes ... http://www.reportlinker.com/p0535955/Enzymes-in-Drug-Manufacturing.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical Biocatalysis in pharmaceutical ... enzyme and genomics technologies that are increasing ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
... drugs to combat or cure human disease often involves a ... clearly into a living mouse,s innards has real value. ... interior of laboratory mice, the view becomes so murky several ... divining the future from the rodent,s entrails than they do ...
Cached Biology News:Reportlinker Adds Enzymes in Drug Manufacturing 2Reportlinker Adds Enzymes in Drug Manufacturing 3Reportlinker Adds Enzymes in Drug Manufacturing 4Reportlinker Adds Enzymes in Drug Manufacturing 5Reportlinker Adds Enzymes in Drug Manufacturing 6Novel pathway regulating angiogenesis may fight retinal disease, cancers 2Better viewing through fluorescent nanotubes when peering into innards of a mouse 2Better viewing through fluorescent nanotubes when peering into innards of a mouse 3
Includes USB cable, custom driver and one roll of thermal paper...
Newborn Bovine Serum Heat-Inactivated...
Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
Biology Products: